At close: December 20 at 4:00:02 PM EST
After hours: December 20 at 6:44:26 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
15,610.00
17,488.00
15,935.00
12,853.00
739.63
Cost of Revenue
5,518.00
2,888.00
2,859.00
3,023.00
237.71
Gross Profit
10,092.00
14,600.00
13,076.00
9,830.00
501.92
Operating Expense
121,715.00
87,984.00
51,846.00
43,627.00
59,591.05
Operating Income
-111,623.00
-73,384.00
-38,770.00
-33,797.00
-59,089.13
Net Non Operating Interest Income Expense
-3,584.00
-2,807.00
-1,248.00
-729.00
-673.64
Other Income Expense
-4,268.00
-2,311.00
-997.00
-53.00
--
Pretax Income
-119,475.00
-78,502.00
-41,015.00
-34,579.00
-59,762.77
Net Income Common Stockholders
-119,475.00
-78,502.00
-41,015.00
-34,579.00
-59,762.77
Diluted NI Available to Com Stockholders
-119,475.00
-78,502.00
-41,015.00
-34,579.00
-59,762.77
Basic EPS
-1.62
-1.21
-0.67
-0.70
-1.76
Diluted EPS
-1.62
-1.21
-0.67
-0.70
-1.76
Basic Average Shares
73,957.55
64,993.48
60,958.86
49,677.74
33,888.43
Diluted Average Shares
73,957.55
64,993.48
60,958.86
49,677.74
33,888.43
Total Operating Income as Reported
-111,623.00
-73,384.00
-38,770.00
-33,797.00
-59,089.13
Total Expenses
127,233.00
90,872.00
54,705.00
46,650.00
59,828.76
Net Income from Continuing & Discontinued Operation
-119,475.00
-78,502.00
-41,015.00
-34,579.00
-59,762.77
Normalized Income
-115,207.00
-76,191.00
-40,018.00
-34,526.00
-59,762.77
Interest Income
6,498.00
3,466.00
1,090.00
33.00
184.36
Interest Expense
10,082.00
6,273.00
2,338.00
762.00
858.00
Net Interest Income
-3,584.00
-2,807.00
-1,248.00
-729.00
-673.64
EBIT
-109,393.00
-72,229.00
-38,677.00
-33,817.00
-58,904.77
EBITDA
-107,208.00
-70,051.00
-35,030.00
-28,205.00
-55,775.19
Reconciled Cost of Revenue
5,518.00
2,888.00
2,859.00
3,023.00
237.71
Reconciled Depreciation
2,185.00
2,178.00
3,647.00
5,612.00
3,129.58
Net Income from Continuing Operation Net Minority Interest
-119,475.00
-78,502.00
-41,015.00
-34,579.00
-59,762.77
Total Unusual Items Excluding Goodwill
-4,268.00
-2,311.00
-997.00
-53.00
--
Total Unusual Items
-4,268.00
-2,311.00
-997.00
-53.00
--
Normalized EBITDA
-102,940.00
-67,740.00
-34,033.00
-28,152.00
-55,775.19
12/31/2020 - 7/26/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
UTHR United Therapeutics Corporation
359.58
-0.16%
MNKD MannKind Corporation
6.85
+8.73%
VRNA Verona Pharma plc
42.02
+1.94%
NRIX Nurix Therapeutics, Inc.
19.83
-1.05%
RYTM Rhythm Pharmaceuticals, Inc.
56.12
+1.15%
VRCA Verrica Pharmaceuticals Inc.
0.6942
+2.65%
MREO Mereo BioPharma Group plc
3.3500
+1.82%
OCUL Ocular Therapeutix, Inc.
8.50
+0.59%
SLNO Soleno Therapeutics, Inc.
45.18
-0.04%
AKRO Akero Therapeutics, Inc.
29.34
+3.31%